Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 171 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Incontinence, Urinary and Urinary Bladder, Overactive Clear all
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB

NCT06789406
View directory record Official record
Conditions
Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Interventions
Axonics SNM System INS Model 5101 (R20)
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Active, not recruiting Not applicable Interventional

INTIBIA Pivotal Study

NCT05250908
View directory record Official record
Conditions
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
Interventions
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
22 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Not applicable Interventional Results available

Modern Urodynamics System Efficacy (MUSE) Study

NCT05959655
View directory record Official record
Conditions
Urologic Diseases, Urodynamics
Interventions
Glean Urodynamics System
Device
Lead sponsor
Bright Uro
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Murrieta, California • Newport Beach, California • East Setauket, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

NCT04570605
View directory record Official record
Conditions
Overactive Bladder, Voiding Disorders, Incontinence, Urinary
Interventions
parasacral transcutaneous electrical nerve stimulation (PTENS), Standard Urotherapy
Device · Other
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 23, 2026, 8:19 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Not applicable Interventional Results available

Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation

NCT03547518
View directory record Official record
Conditions
Overactive Bladder
Interventions
PTNS treatment, Sham treatment
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Not applicable Interventional Results available

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

NCT03556891
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
15
States / cities
Downey, California • Redwood City, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 4 Interventional Results available

Procedural Discomfort Related to Number of Intradetrusor Botox Injections

NCT05652036
View directory record Official record
Conditions
Overactive Bladder
Interventions
Intradetrusor Botox Injections
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Withdrawn No phase listed Observational

Direct Full-stage Implantation of Sacral Neuromodulation

NCT03697954
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urge Incontinence
Interventions
full stage implantation of sacral neuromodulation
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 100 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 4 Interventional

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

NCT00127270
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Darifenacin, Behavioral therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Timeline
2005 – 2006
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions
Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
22 Years to 80 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910520
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 4 Interventional Results available

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions
Axonics SNM System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

NCT00196404
View directory record Official record
Conditions
Urinary Incontinence
Interventions
DR-3001a, DR-3001b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Overactive Bladder Treatment Access and Adherence

NCT06094543
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Incontinence
Interventions
Patient Engagement Tool
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Not applicable Interventional

Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy

NCT07662824
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
Interventions
Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation, Questionnaire Administration, Referral
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Not listed Not applicable Interventional

Painless Laser Therapy for Overactive Bladder

NCT01569061
View directory record Official record
Conditions
Overactive Bladder
Interventions
LCT-1000TM (Manufacturer: LiteCure)
Device
Lead sponsor
Zipper Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Mirabegron For Erectile Dysfunction

NCT02916693
View directory record Official record
Conditions
Erectile Dysfunction, Overactive Bladder, Urinary Incontinence
Interventions
Mirabegron
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 23, 2026, 8:19 AM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 23, 2026, 8:19 AM EDT